Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Acute Phase	STARTED	Atomoxetine/Atomoxetine	120
Acute Phase	STARTED	Placebo/Atomoxetine	89
Acute Phase	COMPLETED	Atomoxetine/Atomoxetine	86
Acute Phase	COMPLETED	Placebo/Atomoxetine	73
Acute Phase	NOT COMPLETED	Atomoxetine/Atomoxetine	34
Acute Phase	NOT COMPLETED	Placebo/Atomoxetine	16
Open-Label Phase	STARTED	Atomoxetine/Atomoxetine	84
Open-Label Phase	STARTED	Placebo/Atomoxetine	71
Open-Label Phase	COMPLETED	Atomoxetine/Atomoxetine	74
Open-Label Phase	COMPLETED	Placebo/Atomoxetine	59
Open-Label Phase	NOT COMPLETED	Atomoxetine/Atomoxetine	10
Open-Label Phase	NOT COMPLETED	Placebo/Atomoxetine	12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00607919/flow